nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.00205	0.00205	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—EGFR—bile duct cancer	0.00203	0.00203	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—ERBB2—bile duct cancer	0.00202	0.00202	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—EGFR—bile duct cancer	0.00202	0.00202	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—RNF43—bile duct cancer	0.00201	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—NRAS—bile duct cancer	0.00201	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—bile duct cancer	0.00201	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—ERBB2—bile duct cancer	0.00201	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—bile duct cancer	0.00201	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—ERBB2—bile duct cancer	0.002	0.002	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—NRAS—bile duct cancer	0.002	0.002	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—ERBB2—bile duct cancer	0.00199	0.00199	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bile duct cancer	0.00197	0.00197	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—EGFR—bile duct cancer	0.00197	0.00197	CbGpPWpGaD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—bile duct cancer	0.00197	0.00197	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—bile duct cancer	0.00196	0.00196	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—MMP9—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—HRAS—bile duct cancer	0.00187	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—ERBB2—bile duct cancer	0.00187	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—bile duct cancer	0.00187	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—ERBB2—bile duct cancer	0.00187	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—KRAS—bile duct cancer	0.00186	0.00186	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—ERBB2—bile duct cancer	0.00186	0.00186	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—bile duct cancer	0.00184	0.00184	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—bile duct cancer	0.00183	0.00183	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—ERBB2—bile duct cancer	0.00183	0.00183	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.00182	0.00182	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—HRAS—bile duct cancer	0.00182	0.00182	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—bile duct cancer	0.00181	0.00181	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—IL6—bile duct cancer	0.00179	0.00179	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—HRAS—bile duct cancer	0.00176	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—HRAS—bile duct cancer	0.00176	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—IL6—bile duct cancer	0.00174	0.00174	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—ERBB2—bile duct cancer	0.00173	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—KRAS—bile duct cancer	0.00173	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—IL6—bile duct cancer	0.00173	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—KRAS—bile duct cancer	0.00172	0.00172	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—NRAS—bile duct cancer	0.00171	0.00171	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—IL6—bile duct cancer	0.00168	0.00168	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—IL6—bile duct cancer	0.00168	0.00168	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—bile duct cancer	0.00166	0.00166	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—bile duct cancer	0.00166	0.00166	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—NRAS—bile duct cancer	0.00164	0.00164	CbGpPWpGaD
Temsirolimus—MTOR—Disease—RNF43—bile duct cancer	0.00162	0.00162	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—NRAS—bile duct cancer	0.00161	0.00161	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—bile duct cancer	0.00158	0.00158	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—HRAS—bile duct cancer	0.00158	0.00158	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—FAR2—bile duct cancer	0.00158	0.00158	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—bile duct cancer	0.00156	0.00156	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—EGFR—bile duct cancer	0.00156	0.00156	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—NRAS—bile duct cancer	0.00154	0.00154	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—NRAS—bile duct cancer	0.00153	0.00153	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—NRAS—bile duct cancer	0.00152	0.00152	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—IL6—bile duct cancer	0.00152	0.00152	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—NRAS—bile duct cancer	0.00151	0.00151	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—bile duct cancer	0.00149	0.00149	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—bile duct cancer	0.00149	0.00149	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—bile duct cancer	0.00149	0.00149	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—HRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—KRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—EGFR—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—HRAS—bile duct cancer	0.00146	0.00146	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—NRAS—bile duct cancer	0.00142	0.00142	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—NRAS—bile duct cancer	0.00142	0.00142	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—bile duct cancer	0.00142	0.00142	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—NRAS—bile duct cancer	0.00141	0.00141	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—IL6—bile duct cancer	0.00141	0.00141	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—KRAS—bile duct cancer	0.00141	0.00141	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—EGFR—bile duct cancer	0.0014	0.0014	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—NRAS—bile duct cancer	0.0014	0.0014	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—IL6—bile duct cancer	0.0014	0.0014	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—EGFR—bile duct cancer	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—bile duct cancer	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—NRAS—bile duct cancer	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—bile duct cancer	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—Disease—IDH1—bile duct cancer	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—EGFR—bile duct cancer	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—KRAS—bile duct cancer	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—EGFR—bile duct cancer	0.00138	0.00138	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bile duct cancer	0.00136	0.00136	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—bile duct cancer	0.00136	0.00136	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—KRAS—bile duct cancer	0.00132	0.00132	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—NRAS—bile duct cancer	0.00132	0.00132	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—KRAS—bile duct cancer	0.00132	0.00132	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—bile duct cancer	0.00132	0.00132	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TGFBR2—bile duct cancer	0.00131	0.00131	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—KRAS—bile duct cancer	0.00131	0.00131	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—KRAS—bile duct cancer	0.0013	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—EGFR—bile duct cancer	0.0013	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—EGFR—bile duct cancer	0.0013	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.0013	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—EGFR—bile duct cancer	0.00129	0.00129	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—bile duct cancer	0.00128	0.00128	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—ERBB2—bile duct cancer	0.00128	0.00128	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.00128	0.00128	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—EGFR—bile duct cancer	0.00127	0.00127	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—HRAS—bile duct cancer	0.00125	0.00125	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—SMAD4—bile duct cancer	0.00124	0.00124	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—bile duct cancer	0.00124	0.00124	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—HRAS—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—KRAS—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—KRAS—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—KRAS—bile duct cancer	0.00122	0.00122	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.0012	0.0012	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—EGFR—bile duct cancer	0.0012	0.0012	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—KRAS—bile duct cancer	0.0012	0.0012	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—IL6—bile duct cancer	0.0012	0.0012	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.0012	0.0012	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—FAR2—bile duct cancer	0.00119	0.00119	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—HRAS—bile duct cancer	0.00118	0.00118	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.00115	0.00115	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.00115	0.00115	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—KRAS—bile duct cancer	0.00113	0.00113	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RNF43—bile duct cancer	0.00113	0.00113	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—HRAS—bile duct cancer	0.00113	0.00113	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—IL6—bile duct cancer	0.00113	0.00113	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—HRAS—bile duct cancer	0.00112	0.00112	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—FAR2—bile duct cancer	0.00112	0.00112	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—HRAS—bile duct cancer	0.00112	0.00112	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	0.00112	0.00112	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—HRAS—bile duct cancer	0.00111	0.00111	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—HRAS—bile duct cancer	0.00111	0.00111	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.00109	0.00109	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—TGFB1—bile duct cancer	0.00109	0.00109	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.00109	0.00109	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—IL6—bile duct cancer	0.00108	0.00108	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—IL6—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—IDH2—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—IL6—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—IL6—bile duct cancer	0.00106	0.00106	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.00104	0.00104	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—HRAS—bile duct cancer	0.00104	0.00104	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—HRAS—bile duct cancer	0.00104	0.00104	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—HRAS—bile duct cancer	0.00103	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.00102	0.00102	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—HRAS—bile duct cancer	0.00102	0.00102	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—IL6—bile duct cancer	0.000998	0.000998	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—IL6—bile duct cancer	0.000998	0.000998	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000998	0.000998	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—IL6—bile duct cancer	0.000989	0.000989	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.00098	0.00098	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—IL6—bile duct cancer	0.000976	0.000976	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—NRAS—bile duct cancer	0.000971	0.000971	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—HRAS—bile duct cancer	0.000965	0.000965	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NOS2—bile duct cancer	0.000925	0.000925	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.000923	0.000923	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TGFBR2—bile duct cancer	0.00092	0.00092	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—IDH1—bile duct cancer	0.000919	0.000919	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—GNAS—bile duct cancer	0.000887	0.000887	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—EGFR—bile duct cancer	0.000884	0.000884	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000884	0.000884	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SMAD4—bile duct cancer	0.000871	0.000871	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KRAS—bile duct cancer	0.000835	0.000835	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—bile duct cancer	0.000792	0.000792	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—IDH2—bile duct cancer	0.000772	0.000772	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	0.000759	0.000759	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	0.000742	0.000742	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TGFBR2—bile duct cancer	0.000739	0.000739	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—FAR2—bile duct cancer	0.000735	0.000735	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HGF—bile duct cancer	0.000735	0.000735	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ERBB2—bile duct cancer	0.000728	0.000728	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—IL6—bile duct cancer	0.000725	0.000725	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—HRAS—bile duct cancer	0.00071	0.00071	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	0.000706	0.000706	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SMAD4—bile duct cancer	0.000699	0.000699	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB2—bile duct cancer	0.000699	0.000699	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB2—bile duct cancer	0.000696	0.000696	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTGS2—bile duct cancer	0.00068	0.00068	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—IL6—bile duct cancer	0.00068	0.00068	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—IDH1—bile duct cancer	0.000664	0.000664	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—SLC5A5—bile duct cancer	0.000606	0.000606	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—IDH2—bile duct cancer	0.000583	0.000583	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—NRAS—bile duct cancer	0.000554	0.000554	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—IDH2—bile duct cancer	0.000549	0.000549	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000548	0.000548	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.000536	0.000536	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—NRAS—bile duct cancer	0.000532	0.000532	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NRAS—bile duct cancer	0.000529	0.000529	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000526	0.000526	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NOS2—bile duct cancer	0.00052	0.00052	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TGFBR2—bile duct cancer	0.000517	0.000517	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EGFR—bile duct cancer	0.000504	0.000504	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—IDH1—bile duct cancer	0.000501	0.000501	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GNAS—bile duct cancer	0.000499	0.000499	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000497	0.000497	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TGFB1—bile duct cancer	0.000492	0.000492	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SMAD4—bile duct cancer	0.00049	0.00049	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB2—bile duct cancer	0.000487	0.000487	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—bile duct cancer	0.000484	0.000484	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—bile duct cancer	0.000482	0.000482	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—bile duct cancer	0.000476	0.000476	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—IDH1—bile duct cancer	0.000472	0.000472	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GNAS—bile duct cancer	0.000471	0.000471	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—bile duct cancer	0.000458	0.000458	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—bile duct cancer	0.000456	0.000456	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000442	0.000442	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—SLC5A5—bile duct cancer	0.000438	0.000438	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB2—bile duct cancer	0.000424	0.000424	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MMP9—bile duct cancer	0.000418	0.000418	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—bile duct cancer	0.000405	0.000405	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—bile duct cancer	0.000391	0.000391	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—bile duct cancer	0.000389	0.000389	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—IL6—bile duct cancer	0.000388	0.000388	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—bile duct cancer	0.000387	0.000387	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—bile duct cancer	0.000383	0.000383	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRAS—bile duct cancer	0.000371	0.000371	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—IL6—bile duct cancer	0.000371	0.000371	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—IDH2—bile duct cancer	0.000359	0.000359	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TGFB1—bile duct cancer	0.000344	0.000344	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GNAS—bile duct cancer	0.00034	0.00034	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—bile duct cancer	0.000338	0.000338	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC5A5—bile duct cancer	0.000331	0.000331	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRAS—bile duct cancer	0.000322	0.000322	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—bile duct cancer	0.000319	0.000319	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC5A5—bile duct cancer	0.000312	0.000312	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—IDH1—bile duct cancer	0.000309	0.000309	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRAS—bile duct cancer	0.000298	0.000298	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—bile duct cancer	0.000294	0.000294	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—bile duct cancer	0.000284	0.000284	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—bile duct cancer	0.000278	0.000278	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TGFB1—bile duct cancer	0.000277	0.000277	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—bile duct cancer	0.000274	0.000274	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—bile duct cancer	0.000271	0.000271	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—bile duct cancer	0.000271	0.000271	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL6—bile duct cancer	0.00026	0.00026	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GNAS—bile duct cancer	0.000257	0.000257	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—bile duct cancer	0.000256	0.000256	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—bile duct cancer	0.000253	0.000253	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GNAS—bile duct cancer	0.000242	0.000242	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—bile duct cancer	0.000236	0.000236	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MMP9—bile duct cancer	0.000235	0.000235	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL6—bile duct cancer	0.000226	0.000226	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—bile duct cancer	0.000218	0.000218	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRAS—bile duct cancer	0.000208	0.000208	CbGpPWpGaD
Temsirolimus—MTOR—Disease—IL6—bile duct cancer	0.000208	0.000208	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC5A5—bile duct cancer	0.000204	0.000204	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TGFB1—bile duct cancer	0.000194	0.000194	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—bile duct cancer	0.00019	0.00019	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—bile duct cancer	0.000183	0.000183	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—bile duct cancer	0.000179	0.000179	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—bile duct cancer	0.000159	0.000159	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GNAS—bile duct cancer	0.000158	0.000158	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—bile duct cancer	0.000153	0.000153	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL6—bile duct cancer	0.000146	0.000146	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—bile duct cancer	0.000138	0.000138	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—bile duct cancer	0.00013	0.00013	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—bile duct cancer	8.5e-05	8.5e-05	CbGpPWpGaD
